🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

203+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 203 recruiting trials for “combined-hepatocellular-carcinoma-and-cholangiocarcinoma

Phase 2RecruitingNCT06133062

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

🏥 Chang Gung Memorial Hospital📍 1 site📅 Started Nov 2023View details ↗
Enrolling by InvitationNCT05429190

Validation of SMS Protocol for HCC Screening in High-risk Patients

👨‍⚕️ Prof. Dr. de Man, Erasmus Medical Center📍 6 sites📅 Started Nov 2023View details ↗
Phase 2RecruitingNCT05440864

Durvalumab and Tremelimumab in Resectable HCC

👨‍⚕️ Gonzalo Sapisochin, MD, Univeristy Health Network📍 3 sites📅 Started Oct 2023View details ↗
Phase 1RecruitingNCT06010862

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

👨‍⚕️ Fei Li, M.D, The First Affiliated Hospital of Nanchang University📍 1 site📅 Started Sep 2023View details ↗
RecruitingNCT05263830

Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy

👨‍⚕️ Manon ALLAIRE, Dr, Assistance Publique - Hôpitaux de Paris📍 1 site📅 Started Sep 2023View details ↗
RecruitingNCT06060769

Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging

👨‍⚕️ Yaqin Zhang, MD, Ph.D, Fifth Affiliated Hospital, Sun Yat-Sen University📍 1 site📅 Started Sep 2023View details ↗
Phase 3RecruitingNCT05823311

Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

🏥 Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Sep 2023View details ↗
RecruitingNCT06036563

Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing

🏥 Air Force Military Medical University, China📍 8 sites📅 Started Sep 2023View details ↗
Phase 1, PHASE2RecruitingNCT05874414

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

👨‍⚕️ Peter Lichten, M.D., Genfit📍 11 sites📅 Started Aug 2023View details ↗
Phase 4RecruitingNCT07132515

Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

🏥 Mansoura University📍 1 site📅 Started Aug 2023View details ↗
Phase 2RecruitingNCT05451043

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

🏥 AHS Cancer Control Alberta📍 1 site📅 Started Jul 2023View details ↗
RecruitingNCT06899854

Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer.

🏥 Fondazione IRCCS Policlinico San Matteo di Pavia📍 1 site📅 Started Jun 2023View details ↗
Phase 2RecruitingNCT06335927

HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

🏥 Fudan University📍 1 site📅 Started May 2023View details ↗
Phase 3RecruitingNCT05862337

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

🏥 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.📍 67 sites📅 Started May 2023View details ↗
Phase 3RecruitingNCT05876754

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

🏥 Servier Affaires Médicales📍 84 sites📅 Started May 2023View details ↗
Phase 2RecruitingNCT06370065

Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

🏥 Tianjin Medical University Cancer Institute and Hospital📍 1 site📅 Started Apr 2023View details ↗
NARecruitingNCT05146297

Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials

👨‍⚕️ Nina Bickell, Icahn School of Medicine at Mount Sinai📍 3 sites📅 Started Apr 2023View details ↗
Phase 1RecruitingNCT05568680

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

👨‍⚕️ Laura Johnson, PhD, Verismo Therapeutics📍 4 sites📅 Started Mar 2023View details ↗
Phase 1RecruitingNCT05791448

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

👨‍⚕️ Anthony B El-Khoueiry, MD, University of Southern California📍 2 sites📅 Started Mar 2023View details ↗
NARecruitingNCT05764551

The Application of Serum DNA Methylation for Patients With HCC

👨‍⚕️ Po-Yueh Chen, M.D, Ditmanson Medical Foundation Chiayi Christian Hospital📍 1 site📅 Started Mar 2023View details ↗
← PreviousPage 7 of 11Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →